Innovation Pharmaceuticals Inc (IPIX)

[PlentyParanoid]

A few comments:
"I'm not sure why this footnote appears at the end of the paragraph shown"

1. Polymedix did ran a p2 ABSSSI trial with Brilacidin plus a study for causes of paraesthesia. The ION channel inhibition business is the result of the latter.
Links to Polymedix presentations:
Polymedix P2 Brilacidin trial at ClinicalTrials.gov:
https://clinicaltrials.gov/ct2/show/NCT01211470?term=PMX30063&rank=2
Polymedix Summary for P2 Brilacidin trial:
http://files.shareholder.com/downloads/ABEA-4ITCYZ/1997024712x0x611205/FEA66C67-D02F-4FF2-B230-AA711F46ED7F/PMX-30063_Antibiotic_Fact_Sheet_Nov_2012_.pdf
Paraesthesia:
http://files.shareholder.com/downloads/ABEA-4ITCYZ/0x0x502110/5074f905-da25-4a90-95e0-1b443a14b944/Investigation_of_Potential_Mechanisms_Paraesthesia_5-7-10.pdf

2. We may have been a bit off by using $30M as a cost for FDA requested Brilacidin phase 3 ABSSSI trials. Rosen law firm gives an estimate of $100M in their class action suit. We can, of course, discuss how reliable Rosen's estimate is, especially in light of some rather innovative (but profoundly silly. No wonder they P.O.ed the judge) mixing of biomarker and substitute endpoint definitions by Rosen.

Link to Rosen class action suit (now dismissed). The estimate is on page 15:
http://securities.stanford.edu/filings-documents/1056/CC00_07/2016111_r01c_15CV07194.pdf

But, if Rosen estimate is even half right Cellceutix was far from having financial resources to run ABSSSI p3 trials.